Latest News
-
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D., co-leading... -
PASADENA, Calif. – Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS). ARO-APOC3 is the company’s investigational RNA interference (RNAi) therapeutic...
-
An expert panel failed to reach consensus on how to treat some patients with severe hemophilia A, suggesting that further study is needed where the optimal treatment remains equivocal, according to research published in the Journal of Blood Medicine. Hemophilia A is linked with a reduced quality of life (QoL)...
Videos
Rare disease spotlight
3/3
This has great implications for treatment as perampenal is a selective blocker of AMPAR recepters and can be used in patients suffering from GoF variants. #genetics #epilepsy #PrecisionMedicine
@epilepsy_scot @EpiCARE_ERN @eurordis @CheckOrphan @rarediseaseuk @eurordis
¿Cuáles son los tipos de cáncer que más afectan a los niños? https://blogaecc.azurewebsites.net/cancer-infantil-tumores-frecuentes/
#Myeloma is a rare, incurable disease of the bone marrow and accounts for approximately 1% of cancers.
Click on the link to watch the video that explains what myeloma is, how it is diagnosed, and its symptoms and treatments:
▶️ https://www.mpeurope.org/what-we-do/publications/educational-clips/
#thinkmyeloma #thinkALamy